Literature DB >> 10976985

Type V osteogenesis imperfecta: a new form of brittle bone disease.

F H Glorieux1, F Rauch, H Plotkin, L Ward, R Travers, P Roughley, L Lalic, D F Glorieux, F Fassier, N J Bishop.   

Abstract

Osteogenesis imperfecta (OI) is commonly subdivided into four clinical types. Among these, OI type IV clearly represents a heterogeneous group of disorders. Here we describe 7 OI patients (3 girls), who would typically be classified as having OI type IV but who can be distinguished from other type IV patients. We propose to call this disease entity OI type V. These children had a history of moderate to severe increased fragility of long bones and vertebral bodies. Four patients had experienced at least one episode of hyperplastic callus formation. The family history was positive for OI in 3 patients, with an autosomal dominant pattern of inheritance. All type V patients had limitations in the range of pronation/supination in one or both forearms, associated with a radiologically apparent calcification of the interosseous membrane. Three patients had anterior dislocation of the radial head. A radiodense metaphyseal band immediately adjacent to the growth plate was a constant feature in growing patients. Lumbar spine bone mineral density was low and similar to age-matched patients with OI type IV. None of the type V patients presented blue sclerae or dentinogenesis imperfecta, but ligamentous laxity was similar to that in patients with OI type IV. Levels of biochemical markers of bone metabolism generally were within the reference range, but serum alkaline phosphatase and urinary collagen type I N-telopeptide excretion increased markedly during periods of active hyperplastic callus formation. Qualitative histology of iliac biopsy specimens showed that lamellae were arranged in an irregular fashion or had a meshlike appearance. Quantitative histomorphometry revealed decreased amounts of cortical and cancellous bone, like in OI type IV. However, in contrast to OI type IV, parameters that reflect remodeling activation on cancellous bone were mostly normal in OI type V, while parameters reflecting bone formation processes in individual remodeling sites were clearly decreased. Mutation screening of the coding regions and exon/intron boundaries of both collagen type I genes did not reveal any mutations affecting glycine codons or splice sites. In conclusion, OI type V is a new form of autosomal dominant OI, which does not appear to be associated with collagen type I mutations. The genetic defect underlying this disease remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976985     DOI: 10.1359/jbmr.2000.15.9.1650

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  112 in total

1.  Modeling the benefits of pamidronate in children with osteogenesis imperfecta.

Authors:  Robert Lindsay
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year.

Authors:  Joanne Ruck; Noémi Dahan-Oliel; Kathleen Montpetit; Frank Rauch; François Fassier
Journal:  J Child Orthop       Date:  2011-05-08       Impact factor: 1.548

3.  A boy with blue sclera and recurrent fractures.

Authors:  N Md Shukri; I Mohamad; R Salim
Journal:  Malays Fam Physician       Date:  2015-04-30

4.  Case report: osteogenesis imperfecta Elusive cause of fractures.

Authors:  Elizabeth L Strevel; Alexandra Papaioannou; Jonathan D Adachi; Marty McNamara
Journal:  Can Fam Physician       Date:  2005-12       Impact factor: 3.275

Review 5.  Unexplained fractures in infancy: looking for fragile bones.

Authors:  Nick Bishop; Alan Sprigg; Ann Dalton
Journal:  Arch Dis Child       Date:  2007-03       Impact factor: 3.791

Review 6.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

Review 7.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

8.  Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.

Authors:  Y Liu; D Ma; F Lv; X Xu; J Wang; W Xia; Y Jiang; O Wang; X Xing; W Yu; J Wang; J Sun; L Song; Y Zhu; H Yang; J Wang; M Li
Journal:  Osteoporos Int       Date:  2017-07-19       Impact factor: 4.507

Review 9.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

10.  Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation.

Authors:  Bahar Kasaai; Marie-Hélène Gaumond; Pierre Moffatt
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.